Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA
Belova59 / Pixabay

Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA

According to a story from pm360online.com, the pharmaceutical company Roche recently announced that its investigational therapy risdiplam has awarded PRIME designation from the European Medicines Agency (EMA). The drug has…

Continue Reading Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA